Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
P/S ratio for Portage Biotech Inc. (PRTG)
P/S ratio as of 2024: 0.00
According to Portage Biotech Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2023 the company had a P/S ratio of 0.00.
P/S ratio history for Portage Biotech Inc. from 1998 to 2024
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2024 | 0.00 |
| 2023 | 0.00 |
| 2022 | 0.00 |
| 2021 | 0.00 |
| 2020 | 0.00 |
| 2019 | 0.00 |
| 2018 | 0.00 |
| 2017 | 0.00 |
| 2016 | 0.00 |
| 2015 | 0.00 |
| 2014 | 0.00 |
| 2013 | 2907.74 |
| 2012 | 0.00 |
| 2011 | 0.00 |
| 2010 | 0.00 |
| 2009 | 1424.95 |
| 2008 | 692.99 |
| 2007 | 253.88 |
| 2006 | 112.90 |
| 2005 | 694.70 |
| 2004 | 0.00 |
| 2003 | 417.17 |
| 2002 | 660.69 |
| 2001 | 166.06 |
| 2000 | 10599.54 |
| 1999 | 0.00 |
| 1998 | 0.00 |